The Impact of HCV eradication on HBAIC in Genotype 3 Chronic HCV Diabetic Patients Authors

Objective: Hepatitis C Virus (HCV) is a global health concern. WHO estimated that it affects a 170 million people worldwide. In Pakistan, 6.8% of adult population exhibits presence of active disease. With the rise of DAAs especially Sofosbuvir and Velpatasvir the ETR and SVR is remarkable. Patients who secure seroconversion following DAA treatment experience a drop in their HOMA-IR levels, in contrast to those who don't. It means that there are metabolic benefits of HCV eradication. Based on this hypothesis we evaluated the benefit on HBAIC in patients achieving ETR. Methods: The study sample comprised of 100 type 2 diabetics who attended Gastroenterology clinic at GTTH, a tertiary care hospital in Lahore for treatment of HCV infection. All the confirmed type 2 diabetes cases on any therapy were included in the study sample. Data was analyzed using SPSS Statistics version 24. Results: Out of study sample of 100 patients, 100% achieved an end of treatment response (ETR). In our study, mean difference in fasting blood sugar (FBS) from baseline to ETR was found to be a decrease of 48.70 ± 22.20mg/dL (p Value<0.05). Similarly, the mean difference RBS over the same duration showed a reduction of 98.00 ± 39.70 mg/dL (p value <0.05) Quite interestingly, HbA1c levels also showed a decline of mean difference of 1.10 ± 0.82% from baseline to the 3 months mark (p value<0.05) Conclusion: Successful eradication of HCV does lead to improvement in Diabetes control in type 2DM.